Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions

Keyphrases

• Chronic Myeloid Leukemia 100%
• Tyrosine Kinase Inhibitor Therapy 100%
• Tyrosine Kinase Inhibitor Discontinuation 80%
• Tyrosine Kinase Inhibitor 40%
• Treatment-free Remission 40%
• Therapeutic Intervention 20%
• Natural Killer Cells 20%
• Patient Selection 20%
• Remission 20%
• Highly Effective 20%
• Molecular Response 20%
• Retreatment 20%
• Hematopoietic Stem Cells 20%
• Clinical Effect 20%
• Moving Forward 20%
• High Probability 20%
• Leukemia Stem Cells 20%
• Financial Impact 20%
• Tyrosine Kinase Inhibitor Treatment 20%
• Sustained Response 20%
• Discontinuation Trial 20%
• BCR-ABL1 Tyrosine Kinase 20%
• Deep Molecular Response 20%

Medicine and Dentistry

• Tyrosine-Kinase Inhibitor 100%
• Chronic Myelogenous Leukemia 100%
• Recurrent Disease 9%
• Natural Killer Cell 9%
• Stem Cell 9%
• Retreatment 9%
• Hematopoietic Cell 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Tyrosine Kinase Inhibitor 100%
• Chronic Myeloid Leukemia 100%
• Remission 27%
• Recurrent Disease 9%